A Study to Evaluate Molecular and Biochemical Testing for Suspected Hereditary Disorders

Overview

About this study

The objectives of this study are to perform molecular and/or biochemical testing in individuals with suspected hereditary disorders, and/or their family members, to further elucidate possible mechanisms of disease and/or inheritance, and/or to help yield a final laboratory diagnosis at the judgement of the original ordering healthcare provider. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Both of the following criteria must be met for inclusion in this study OR Family members who are clinically unaffected or affected with the same suspected disorder as a patient with VUS:

  • Clinically suspected diagnosis of a genetic disorder.
  • All genetic testing performed to date has been equivocal.
  • Examples of “equivocal” results include:
    • A variant or variants of uncertain significance identified in a gene or genes of interest; borderline hypo- or hypermethylation on a previous targeted methylation assay such as methylation-sensitive MLPA; borderline droplet count or copy number detected by ddPCR or qPCR, respectively;
    • A single mutation identified in a gene of interest, such as via Sanger sequencing, next generation sequencing, or chromosomal microarray, associated with an autosomal recessive disorder in which two mutations must be present in order to be causative (i.e., no second mutation was identified); a pathogenic or likely pathogenic finding that is inconsistent with the current clinical phenotype of the patient  (i.e., the patient’s presentation is still unsolved) or inconsistent with the currently known mode of inheritance for a particular genetic disorder.

Exclusion Criteria:

  • Blood transfusion within the past 2 weeks.
  • Previous bone marrow transplant.
  • Chemotherapy or radiation therapy within the past 6 months.

Eligibility last updated 3/7/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Linda Hasadsri, M.D., Ph.D.

Open for enrollment

Contact information:

Makala Amundson

(507) 266-0201

Amundson.Makala@mayo.edu

More information

Publications

Publications are currently not available